The Influence of Phonomotor Treatment on Word Retrieval Abilities in 26 Individuals With Chronic Aphasia: An Open Trial

2015 ◽  
Vol 58 (3) ◽  
pp. 798-812 ◽  
Author(s):  
Diane L. Kendall ◽  
Megan Oelke ◽  
Carmel Elizabeth Brookshire ◽  
Stephen E. Nadeau

Purpose The ultimate goal of aphasia therapy should be to achieve gains in function that generalize to untrained exemplars and daily conversation. Anomia is one of the most disabling features of aphasia. The predominantly lexical/semantic approaches used to treat anomia have low potential for generalization due to the orthogonality of semantic and phonologic representations; this has been borne out in a meta-analysis of treatment studies. The intensive, neurally distributed, phonologic therapy reported here can, in principle, generalize to untrained phonologic sequences because of extant regularities in phonologic sequence knowledge and should, in principle, generalize to production of words trained as well as those untrained. Method Twenty-six persons with chronic aphasia due to stroke were treated, in a staggered (immediate vs. delayed treatment) open trial design, with 60 hr of intensive, multimodal therapy designed to enhance access to and efficiency of phonemes and phonologic sequences. Results There was an absolute increase of 5% in confrontation naming of “untrained” nouns at 3 months, and there were 9% to 10% increases on measures of generalization of phonologic processes. Conclusion The results of this trial demonstrate generalization of training effects on laboratory measures, which were sustained at 3 months, and provide support for the theories that motivated the treatment.

2018 ◽  
Author(s):  
Georgia Salanti ◽  
Adriani Nikolakopoulou ◽  
Alex J Sutton ◽  
Stephan Reichenbach ◽  
Sven Trelle ◽  
...  

ABSTRACTBackground: The important role of network meta-analysis of randomized clinical trials in health technology assessment and guideline development is increasingly recognized. This approach has the potential to obtain conclusive results earlier than with new standalone trials or conventional, pairwise meta-analyses.Methods: Network meta-analyses can also be used to plan future trials. We introduce a four-steps framework to plan a new trial that aims to identify the optimal new design that will update the existing evidence to best serve timely clinical and public health decision making. The new trial designed within this framework does not need to include all competing interventions and comparisons of interest and can contribute direct and indirect evidence to the updated network meta-analysis. We present the method by virtually planning a new trial to compare biologics in rheumatoid arthritis and a new trial to compare two drugs for relapsing-remitting multiple sclerosis.Results: A trial design based on updating the evidence from a network meta-analysis of relevant previous trials may require a considerably smaller sample size to reach the same conclusion compared with a trial designed and analyzed in isolation. Challenges in the approach include the complexity of the methodology and the need for a coherent network meta-analysis of previous trials with little heterogeneity.Conclusions: When used judiciously, conditional trial design could significantly reduce waste in clinical research.


2003 ◽  
pp. 273-286
Author(s):  
Chad Nye ◽  
Renata Whurr

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15181-e15181
Author(s):  
Ganfeng Xie ◽  
Yuzhu Gong ◽  
Shuang Wu ◽  
Chong Li ◽  
Songtao Yu ◽  
...  

e15181 Background: Adverse events (AEs) observed in regorafenib treated metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumors (GIST) often require treatment modification. However, due to dearth of literature reporting AE management, we performed a systematic review and meta-analysis to assess the success of different methods of managing regorafenib-associated AEs and also determined risk factors of the AEs. Methods: A comprehensive search was conducted in PubMed, Embase and Cochrane Library, to retrieve RCTs and observational studies published from inception to May 2018, discussing the management methods of AEs with rate of improvement and risk factors of the AEs. The success rate for each method was evaluated as percentage and compared using chi2-test. Risk factors were presented using Pearson correlation. Results: We identified 28 studies for this analysis (N = 3120 patients; 305 GIST and 2,815 mCRC). Methods used for management included intermittent dose withdrawal (66.7%), delayed treatment schedules (54%), dose reductions (41%), complete drug withdrawal (19%) and preventive measures like dexamethasone and lactose administration or surgery (63.7%). Reduction or improvement in AEs was observed in 57%, 17% and 100% patients after lowering the initial dose, intermittent withdrawal of regorafenib and using other preventive measures, respectively. Patients aged < 65 years had significantly higher occurrence of AEs compared with patients aged ≥65 years (27.6% vs. 71.3%, p = 0.001). A significant positive correlation was observed between the occurrence of all and grade 3AEs with 160mg dose (r = 0.967 and 0.746 respectively; p = 0.001 for both) with no significant correlation observed for 120-mg and 80-mg doses and any gender. Conclusions: Initiating dose of 160mg is a major risk factor for regorafenib associated AEs in mCRC and GIST patients; with intermittent dose reduction, withdrawal, and delayed treatment being the commonly used management strategies. To allay the risk of AEs and maintain the efficacy, 120mg initial dose is recommended for mCRC and GIST patients. However, further studies are required to confirm the results.


Brain Injury ◽  
2013 ◽  
Vol 27 (5) ◽  
pp. 620-631 ◽  
Author(s):  
Agnès Weill-Chounlamountry ◽  
Nathalie Capelle ◽  
Catherine Tessier ◽  
Pascale Pradat-Diehl

Heart ◽  
2016 ◽  
Vol 102 (Suppl 6) ◽  
pp. A24.2-A25
Author(s):  
Yousif Ahmad ◽  
Sayan Sen ◽  
Sukhjinder Nijjer ◽  
Daniel Keene ◽  
Chris Cook ◽  
...  

2016 ◽  
Vol 39 (1) ◽  
pp. 81-95 ◽  
Author(s):  
Lyndsey Nickels ◽  
Belinda McDonald ◽  
Catherine Mason

Sign in / Sign up

Export Citation Format

Share Document